QLIFE HOLDING AB, Interim Report Q1, January to March 2023
New product readyFinancial summary – first quarter 2023 · Revenue in the period amounted to kSEK 123 (10,905). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test activities in Qlife’s markets are now so low that the company has discontinued the production of new COVID test capsules in order to save operating cost. · EBITDA for the period amounted to kSEK -11,574 (-16,295), and net loss kSEK -16,780 (-15,268). · The total cash flow in the first quarter amounted to kSEK -12,110 (-30,736). · Earnings per share before/after dilution for